Objective To describe the use of tranexamic acid (TXA) in trauma care in England and
Wales since the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage …

IntroductionCurrent practice for the treatment of traumatic hemorrhage includes fluid
resuscitation and the administration of blood products. The administration of tranexamic acid …

BACKGROUND Accumulating evidence established the benefit of tranexamic acid (TXA) for
traumatic bleeding in the hospital setting. TXA use in the field (at or near the point of injury …

Following findings of the Clinical Randomisation of an Antifibrinolytic in Significant
Haemorrhage (CRASH‐2) trial, tranexamic acid (TxA) use post trauma is becoming …

Methods This is an ongoing multi-centered, prospective, observational cohort study with a
retrospective chart-review comparison. Trauma patients identified in the prehospital setting …

BACKGROUND: The aim of the CRASH-2 trial was to assess the effects of early
administration of tranexamic acid on death, vascular occlusive events, and blood transfusion …

Background Women are less likely than men to receive some emergency treatments. This
study examines whether the effect of tranexamic acid (TXA) on mortality in trauma patients …

Traumatic hemorrhage accounts for approximately 2 million deaths each year worldwide. 1
In 2010, the results of the Clinical Randomisation of an Antifibrinolytic in Significant …

Background Tranexamic acid (TXA) has been shown to reduce mortality in the treatment of
traumatic hemorrhage. This effect seems most profound when given early after injury. We …

Background The leading cause of preventable death in the military setting is haemorrhage.
Accumulating evidence has established the benefit of tranexamic acid (TXA), an …